Activity, Motor Control & Coordination
Pain - Thermal Allodynia / Hyperalgesia
Pain - Spontaneous Pain - Postural Deficit
Pain - Mechanical Allodynia / Hyperalgesia
Anxiety & Depression Disorder
Learning/Memory - Attention - Addiction
Physiology & Respiratory Research
Metabolism - Food & Drink Intake
Pain
Central Nervous System (CNS)
Neurodegeneration
Sensory system
Motor control
Mood Disorders
Other disorders
Muscular system
Joints
Metabolism
Cross-disciplinary subjects
Preclinical studies and opioids: role in crisis management in the United States Authors
A. Masood, D. Chandrashekhar
Lab
Shri Neminath Jain Bramhacharyashram's Shriman Sureshdada Jain college of pharmacy Jain gurukul, Chandwad, India
Journal
International Journal of Scientific & Engineering Research
Abstract
Quinazoline-4(3H)-ones and its derivatives are versatile nitrogen heterocyclic compounds which have long been known as a promising class of biologically active compounds. Here we have investigated anti-inflammatory and anti-nociceptive potentials of some of the newly synthesized Quinazolines derivatives. Pharmacological activity was evaluated in the animal models of inflammation (Carrageenan induced paw edema, CFA induced inflammatory pain model) and Pain (formalin induced nociception) in male Sprague Dawley rats. We have evaluated T-02 compound and showed notably effective in reducing the not only carrageenan induced paw edema and CFA induced inflammatory pain but also formalin induced nociception. In carrageenan induced paw edema, CFA induced inflammatory pain and formalin induced nociception. W hen given orally, at similar doses produced significant reduction in paw volume, mechanical hyperalgesia (PWT -paw withdrawal threshold) and inhibition of nocifensive behavior (duration of paw licking and bitting) induced by subplanatar formalin injection. T-02 showed most prominent activity in both the animal models. T-02 at 1 mg/kg, 3 mg/kg, and 10 mg/kg significantly lowered nocifensive score in rats. The paw licking behavior in formalin test was more potently suppressed during the late phase (20–40 min, inflammatory) than in early phase (0–5 min, neurogenic) for T-02. Also; in CFA induced inflammatory pain model (T-02) at a dose of 1, 3 and 10 mg/kg significantly reduced the mechanical hyperalgesia (PW T -paw withdrawal threshold) show signs of anti- hyperalgesic activity and in carrageenan induce paw edema model 3 mg/kg, and 10 mg/kg (T-02) significantly reduced the edema reveal anti-inflammatory activity.
BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)
